169447-70-5

Basic information

• Product Name: (S)-1-N-Boc-2-methylpiperazine
• Synonyms: (R)-2-METHYL-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;(R)-2-METHYL-1-BOC-PIPERAZINE;(S)-TERT-BUTYL 2-METHYLPIPERAZINE-1-CARBOXYLATE;(S)-1-N-BOC-2-METHYL PIPERAZINE;(S)-2-METHYL-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;(R)-TERT-BUTYL 2-METHYLPIPERAZINE-1-CARBOXYLATE;(S)-1-Boc-2-methyl-piperazine;Tert-Butyl2(S)-methylpiperazine-1-carboxylate
• CAS NO: 169447-70-5
• Molecular Formula: C₁₀H₂₀N₂O₂
• Molecular Weight: 200.28
• Product Categories: pharmacetical;Piperaizine;Chiral Reagents;Heterocycles
• Mol File: 169447-70-5.mol
• Article Data: 10

Chemical Properties

• Melting Point: 43.0 to 47.0 °C
• Boiling Point: 268.74 °C at 760 mmHg
• Flash Point: 116.33 °C
• Appearance: /
• Density: 0.998 g/cm³
• Vapor Pressure: 0.008mmHg at 25°C
• Refractive Index: 1.459
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• PKA: 8.49±0.40(Predicted)
• CAS DataBase Reference: (S)-1-N-Boc-2-methylpiperazine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-N-Boc-2-methylpiperazine(169447-70-5)
• EPA Substance Registry System: (S)-1-N-Boc-2-methylpiperazine(169447-70-5)

Safety Data

• RIDADR: UN3077
• Hazardous Substances Data: 169447-70-5(Hazardous Substances Data)

Usage

Description

(S)-1-N-Boc-2-methylpiperazine is an organic compound that serves as a key intermediate in the synthesis of various pharmaceutical compounds. It is characterized by its unique molecular structure, which features a Boc-protected piperazine ring with a methyl group at the 2-position. This structure endows it with specific reactivity and selectivity in chemical reactions, making it a valuable building block in the development of novel therapeutic agents.

Uses

Used in Pharmaceutical Industry:
(S)-1-N-Boc-2-methylpiperazine is used as a synthetic intermediate for the preparation of pyrazolo[3,4-b]pyridine dual pharmacophores as PDE4-muscarinic antagonists. These dual pharmacophores have potential applications in the treatment of various diseases, such as chronic obstructive pulmonary disease (COPD), asthma, and inflammatory conditions. The compound's unique structure allows for the development of more effective and selective drugs with improved pharmacological properties.

InChI:InChI=1/C10H20N2O2/c1-8-7-11-5-6-12(8)9(13)14-10(2,3)4/h8,11H,5-7H2,1-4H3/t8-/m1/s1

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 74879-18-8 (S)-2-methylpiperazine 
• 888973-02-2 (2S)-1-piperazinecarboxylic acid, 2-methyl-4-(triphenylmethyl)-1,1-dimethylethyl ester 
• 859517-91-2 C₁₈H₂₆N₂O₄ 
• 132871-10-4 (3S)-1-benzyl-3-methylpiperazine-2,5-dione 
• 132871-12-6 (S)-3-Methyl-1-(phenylmethyl)piperazine 
• 118375-95-4 methyl (S)-2-(2-chloroacetamido)propanoate 
• 169447-69-2 tert-Butyl (S)-2-methyl-4-(phenylmethyl)-1-piperazinecarboxylate 
• 170033-54-2 (S)-<2-<(2-Hydroxyethyl)(phenylmethyl)amino>-1-methyl-2-oxoethyl>carbamic acid 1,1-dimethylethyl ester 
• 170033-57-5 (S)-3-Methyl-1-(phenylmethyl)piperazin-2-one 

Downstream Products

• 1181076-52-7 N-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}-N'-[(6-fluoro-3'-{[(3S)-3-methyl-1-piperazinyl]methyl}-3-biphenylyl)methyl]propanediamide 
• 1181076-54-9 N-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}-N'-[(6-fluoro-3'-{[(3S)-3-methyl-1-piperazinyl]methyl}-3-biphenylyl)methyl]butanediamide 
• 1181077-96-2 N-{[6-chloro-3'-(1-piperazinylmethyl)-3-biphenylyl]methyl}-N'-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}butanediamide 
• 1158989-78-6 1,1-dimethylethyl (2S)-2-methyl-4-{[4-nitro-2-(trifluoromethyl)phenyl]methyl}-1-piperazinecarboxylate 
• 1178904-06-7 N-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}-N'-[(6-fluoro-3'-{[(3S)-3-methyl-1-piperazinyl]methyl}-3-biphenylyl)methyl]-2,6-pyridinedicarboxamide 
• 1181076-56-1 N-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}-N'-[(6-fluoro-3'-{[(3S)-3-methyl-1-piperazinyl]methyl}-3-biphenylyl)methyl]pentanediamide 
• 1181076-83-4 N'-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}-N-[(6-methyl-3'-{[(3S)-3-methyl-1-piperazinyl]methyl}-3-biphenylyl)methyl]-1,1-cyclopropanedicarboxamide 
• 1446819-07-3 tert-butyl (2S)-4-[[2-chloro-4-(morpholin-4-yl)phenyl]methyl]-2-methylpiperazine-1-carboxylate 
• 1446817-51-1 1,1,1,3,3,3-hexafluoropropan-2-yl (2S)-2-methyl-4-[[4-(morpholin-4-yl)-2-(trifluoromethyl)phenyl]methyl]piperazine-1-carboxylate 
• 1446818-66-1 4-(4-[[(3S)-3-methylpiperazin-1-yl]methyl]-3-(trifluoromethyl)phenyl)morpholine 
• 1446817-50-0 1,1,1,3,3,3-hexafluoropropan-2-yl (2S)-4-[[2-fluoro-4-(morpholin-4-yl)phenyl]methyl]-2-methylpiperazine-1-carboxylate 
• 1446818-64-9 4-(4-[[(3S)-3-methylpiperazin-1-yl]methyl]-3-fluorophenyl)morpholine 
• 1446817-79-3 1,1,1,3,3,3-hexafluoropropan-2-yl (2S)-4-[[2-chloro-4-(morpholin-4-yl)phenyl]methyl]-2-methylpiperazine-1-carboxylate 
• 1446819-08-4 4-(3-chloro-4-[[(3S)-3-methylpiperazin-1-yl]methyl]phenyl)morpholine 

Relevant articles and documents

FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS

Provided are fused tricyclic amide compounds, pharmaceutical compositions comprising at least one such fused tricyclic compound, processes for the preparation thereof, and the use thereof in therapy. Disclosed herein are certain tricyclic amide compounds that can be useful for inhibiting multiple (specifically BRAF and/or EGFR-T790M) kinases and for treating disorders mediated thereby.

PHENOXYACETIC ACID DERIVATIVES USEFUL FOR TREATING RESPIRATORY DISEASES

The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.Formula (I)

NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS

Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.